Stacey Bowlin Joins Georgia Bio as Senior Vice President of Industry Engagement and Marketing

Georgia Bio, the state’s life science trade association, announced today the appointment of Stacey Bowlin as the organization’s Senior Vice President of Industry Engagement and Marketing. Bowlin will collaborate closely with Georgia Bio’s CEO on the company's strategic priorities, including the company’s go-to-market positioning and its integrated work with members.

 

“Stacey is an association brand strategist who will help both our members and GA Bio harness change to maximize performance and connectivity with key stakeholders across the state. She’ll be invaluable in driving our company’s strategic initiatives forward as we continue to evolve and grow," said Georgia Bio CEO Maria Thacker Goethe. “We’re very pleased to welcome Stacey to the organization.”

 

Over the course of her career, Bowlin has worked for a range of service organizations delivering marketing and event solutions to drive growth, retention, and revenue. Most recently, Bowlin worked at California Life Sciences, where she served as the association's Senior Vice President of Marketing and Industry Engagement. At CLS, she built a marketing function that included the organization’s communications and profile building efforts, events portfolio, sponsorship and other non-dues revenue initiatives. Stacey also oversaw CLS’ entrepreneurship programs, with an emphasis on expanding opportunities for startup companies, including CLS’s acclaimed FAST advisory program, and new initiatives that support the innovation pipeline. 

 

Previously, she spent more than a decade at the Biotechnology Innovation Organization (BIO), the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. 

 

"I am excited to work with the GA Bio team to amplify their portfolio of programs, events, and initiatives, helping our members advance critical products and services that will transform patient’s lives,” said Stacey Bowlin. “Together, we will continue to focus on the needs of our members.”

 

Georgia Bio also recently welcomed Katie Rogers to the organization. In her role as Director of Innovation & Entrepreneurship, Katie will focus on entrepreneurship initiatives connecting life science startups to resources needed to help them scale their ventures. She will also serve as the liaison for many of Georgia Bio’s committees and networks to ensure strong partnerships.

 

About Georgia Bio


Georgia Bio (GaBio) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, GaBio has served its members by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. GaBio also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. GaBio works to shape public policy, improve access to breakthrough technologies, educate lawmakers, provide member programs, strengthens the workforce pipeline, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. For more information, visit www.gabio.org | www.georgiabioed.org


MEDIA CONTACT:

Melissa Carter

404-920-2043

mcarter@gabio.org

GLS 2025 Year in Review

December 22, 2025
Dear Georgia Life Sciences Community, As we reflect on the past year, I want to extend my sincere thanks to our Georgia Life Sciences members for making it such an impactful one. Your engagement and leadership continue to move our industry forward and advance our shared strategic priorities— driving strong policy, expanding the talent pipeline, and creating intentional spaces for collaboration across Georgia’s life sciences ecosystem. Our Year in Review captures the progress we’ve made together across these priorities and highlights the collective impact our members are having statewide—from strengthening the workforce and supporting manufacturing growth to elevating Georgia’s position as a national life sciences leader. This progress is only possible because of the collaboration, commitment, and insight of our member community. 

Investing in America’s Biopharmaceutical Infrastructure Strengthens the Economy and Supports Union Workers

By Maria Thacker Goethe • December 20, 2025
The biopharmaceutical industry is growing America’s manufacturing and R&D capabilities to develop the next generation of treatments. A recent study from PILMA quantified the impact of the industry’s investment in American infrastructure on the economy and union workforce across 18 states from 2019-2024. The study found that across the 18 states included, the biopharmaceutical industry: Supported the American economy by investing $86.5B in R&D and manufacturing infrastructure and developing 1000+ construction projects at over 700 distinct facilities. Strengthened the American workforce by generating $2.6B in skilled union wages and providing $19M in support for union apprenticeships. The impact of the biopharmaceutical industry’s investment in American manufacturing and union jobs extends beyond direct benefits, spurring additional economic activity in the communities where workers live. This is known as the multiplier effect . On average, every $1 of new investment in a U.S. biopharmaceutical manufacturing facilities generates an additional $1.59 in further economic activity (2.59x times the initial investment value). The industry’s $86.5B investment in R&D and manufacturing infrastructure has a total economic impact of $224B. Check out this resource to learn more about how biopharmaceutical investment in American infrastructure supports America’s workers and communities. For more on how biopharmaceutical companies are investing in America’s future, visit innovation.org/america-investment .

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
MORE POSTS